Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

NOX5 Immunogenic Peptides and Monoclonal Antibodies for the Detection of Cancer and Inflammatory Responses

Posted Sep 28 2011 8:00pm

Description of Invention:
The membrane-associated NADPH oxidase 5 (NOX5) protein is expressed in various fetal tissues, uterus, testis, spleen, lymph nodes and endothelial cells. In addition, the reactive oxygen species (ROS) generated by NOX5 have been shown to participate in signaling cascades regulating proliferation in several cancers and pre-cancerous conditions, such as hairy cell leukemia, melanoma, prostate cancer, and Barret's esophagus. Further, excess ROS produced by NOX5 has been associated with coronary artery disease, inflammation, and atherosclerosis.

The present invention discloses the identification and characterization of a purified monoclonal antibody against NOX5 protein. This NOX5 antibody can detect endogenous levels of NOX5 in human cells and could aid in studies and diagnostic tests of NOX5-based redox signaling involved in cancer, cell growth and differentiation, as well as angiogenic and inflammatory responses. In addition, the NOX5 antibody may have therapeutic applications (e.g. anti-inflammatory, antiangiogenic, or antiproliferative activity) by interfering with NOX5 activation at the cell surface.

Applications:
  • Diagnostic for the detection of NOX5 in human cells and NOX5-based redox signaling
  • Antibody can be used in ELISA, Western Blot, Immunofluorescence, Immunoprecipitation and Immunohistochemistry
  • Tool to aid in the understanding of NOX5’s functional significance in human physiology and pathophysiology
  • Possible therapeutic for the treatment of various human diseases associated with NOX5 and/or ROS


Advantages:
  • Antibody is the only mouse monoclonal commercially available to the best of our knowledge
  • Antibody is highly specific in recognizing the NOX5 protein with greater efficiency and the accurate detection compared to other Nox5 antibodies


Development Status:
Pre-clinical

Inventors:
James H Doroshow (NCI)
Krishnendu K Roy (NCI)
Smitha Antony (NCI)


Patent Status:
HHS, Reference No. E-149-2011/0
US, Application No. 61/471,596 filed 04 Apr 2011


Relevant Publication:
  1. Kamiguti AS, et al. [ PMID 16339585 ]
  2. Brar SS, et al. [ PMID 12686516 ]
  3. Hong J, et al. [ PMID 20086178 ]



For Licensing Information Please Contact:
Whitney Hastings
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: hastingw@mail.nih.gov
Phone: 301-451-7337
Fax: 301-402-0220


Ref No: 2324

Updated: 09/2011

Post a comment
Write a comment:

Related Searches